Q-omics provides the consensus-scored FAM13C profile across patient tissues and cancer cell-line models. FAM13C expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, FAM13C is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, FAM13C RNA expression shows 21,537 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, THCA, and GBM as cancer lineages where FAM13C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM13C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM13C survival associations across molecular data types. FAM13C RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM13C RNA expression–survival associations across cancer types. High FAM13C expression shows unfavorable associations in UVM, but favorable associations in UCEC, LGG, UCS, KIRC and HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for FAM13C RNA expression.
This table summarizes FAM13C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FAM13C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM13C shows lower tumor expression in THCA, LUAD, COAD, UCEC and LUSC and higher tumor expression in LIHC. The THCA box plot shows higher FAM13C RNA expression in normal versus tumor tissue (log2 FC = −1.121, t-test p < 0.001).
This table shows molecular features associated with FAM13C in patient tissues and cancer cell lines. In patient samples, FAM13C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM13C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
